Cerus Corporation (CERS) is a Healthcare stock trading at $2.79 (as of 2026-08-20), with a market capitalization of $562.25M. Figures are sourced from first-party U.S. SEC EDGAR filings and market data.
Cerus Corporation operates as a biomedical products company. The company focuses on developing and commercializing the INTERCEPT Blood System to enhance blood safety. Its INTERCEPT Blood System, a proprietary technology for controlling biological replication that is designed to reduce blood-borne pathogens in donated blood components intended for transfusion. The company offers INTERCEPT Blood Systems for platelets and plasma, which is designed to inactivate blood-borne pathogens in platelets and plasma donated for transfusion; INTERCEPT Blood System for red blood cells to inactivate blood-borne pathogens in red blood cells donated for transfusion; and INTERCEPT Blood System for Cryoprecipitation that uses its plasma system to produce pathogen reduced cryoprecipitated fibrinogen complex for the treatment and control of bleeding, including massive hemorrhage associated with fibrinogen deficiency, as well as pathogen reduced plasma, cryoprecipitate reduced. It sells platelet and plasma systems through its direct sales force and distributors in the United States, Europe, the Commonwealth of Independent States, the Middle East, Latin America, and internationally. The company was incorporated in 1991 and is headquartered in Concord, California.
Cerus develops and commercializes the INTERCEPT Blood System to help reduce blood-borne pathogens in donated blood components, generating revenue from selling INTERCEPT products for platelets and plasma and from related government contract revenue.
Cerus is structurally a consumables-driven model, because INTERCEPT requires kits to treat donated platelets and plasma on an ongoing basis, so product mix tied to kits and cumulative kits sold are key drivers of revenue.
| Plasma | $0.1B |
| Product | $0.1B |
Business quality (Weak): Revenue is modest and the latest period shows negative operating margin, but the product engine appears tied to repeatable INTERCEPT treatment (kit usage), which can support ongoing demand if coverage and utilization hold up.
| Price | $2.79 |
| Market Cap | $562.25M |
| EV / EBITDA | 361.2 |
| Price / Book | 7.95 |
| Price / Sales | 2.59 |
| FCF Yield | -3.1% |
| Revenue (TTM) | $233.80M |
| Net Margin | -6.7% |
| Revenue Growth (YoY) | 16.1% |
| EPS Growth (YoY) | -27.3% |
| FCF Growth (YoY) | -87.0% |
| Altman Z-Score | -3.45 (distress) |
| Sector P/E (Healthcare) | 21.6 |
| Industry P/E (Medical Equipment) | 32.9 |
| Top Institutional Holder | BlackRock, Inc. ($39.27M) |
| Institutional Holders Tracked | 10 |
| Sector | Healthcare |
| Industry | Medical Equipment |
| CEO | William Greenman |
| Employees | 614 |
| Country | US |
| IPO Date | 1997-01-31 |
Data as of 2026-08-20.
Figures sourced from U.S. Securities and Exchange Commission (SEC EDGAR) filings and market data. Not personalized investment advice.